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Hypothalamic histamine H1 receptor-AMPK signaling time-dependently
mediates olanzapine-induced hyperphagia and weight gain in female rats
Abstract

Although second-generation antipsychotics induce severe weight gain and obesity, there is a lack of detailed
knowledge about the progressive development of antipsychotic-induced obesity. This study examined the
hypothalamic histamine H1 receptor and AMP-activated protein kinase (H1R-AMPK) signaling at three
distinctive stages of olanzapine-induced weight gain (day 1-12: early acceleration, day 13-28: middle new
equilibrium, and day 29-36: late heavy weight maintenance). At the early acceleration stage, the rats were
hyperphagic with an underlying mechanism of olanzapine-increased H1R mRNA expression and AMPK
phosphorylation (pAMPK), in which pAMPK levels positively correlated with H1R mRNA expression and
food intake. At the middle stage, when the rats were no longer hyperphagic, the changes in H1R-AMPK
signaling vanished. At the late stage, olanzapine increased H1R mRNA expression but decreased pAMPK
which were positively and negatively correlated with weight gain, respectively. These data suggest a timedependent change of H1R-AMPK signaling, where olanzapine activates AMPK by blocking the H1Rs and
causing hyperphagia in the acute phase. The chronic blockade of H1R may contribute to the late stage of
olanzapine-induced heavy weight maintenance. However, pAMPK was no longer elevated and actually
decreased. This indicates that AMPK acts as an energy sensor and negatively responds to the positive energy
balance induced by olanzapine. Furthermore, we showed that an H1R agonist, 2-(3-trifluoromethylphenyl)
histamine, can significantly inhibit olanzapine-induced hyperphagia and AMPK activation in the mediobasal
hypothalamus in a dose dependent manner. Therefore, lowering H1R-AMPK signaling is an effective
treatment for the olanzapine-induced hyperphagia associated with the development of obesity.
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Summary
Although second-generation antipsychotics induce severe weight gain and obesity, there is a
lack of detailed knowledge about the progressive development of antipsychotic-induced
obesity. This study examined the hypothalamic histamine H1 receptor and AMP-activated
protein kinase (H1R-AMPK) signaling at three distinctive stages of olanzapine-induced weight
gain (day 1-12: early acceleration, day 13-28: middle new equilibrium, and day 29-36: late
heavy weight maintenance). At the early acceleration stage, the rats were hyperphagic with an
underlying mechanism of olanzapine-increased H1R mRNA expression and AMPK
phosphorylation (pAMPK), in which pAMPK levels positively correlated with H1R mRNA
expression and food intake. At the middle stage, when the rats were no longer hyperphagic, the
changes in H1R-AMPK signaling vanished. At the late stage, olanzapine increased H1R
mRNA expression but decreased pAMPK which were positively and negatively correlated
with weight gain, respectively. These data suggest a time-dependent change of H1R-AMPK
signaling, where olanzapine activates AMPK by blocking the H1Rs and causing hyperphagia
in the acute phase. The chronic blockade of H1R may contribute to the late stage of
olanzapine-induced heavy weight maintenance. However, pAMPK was no longer elevated and
actually decreased. This indicates that AMPK acts as an energy sensor and negatively responds
to the positive energy balance induced by olanzapine. Furthermore, we showed that an H1R
agonist, 2-(3-trifluoromethylphenyl) histamine, can significantly inhibit olanzapine-induced
hyperphagia and AMPK activation in the mediobasal hypothalamus in a dose dependent
manner. Therefore, lowering H1R-AMPK signaling is an effective treatment for the
olanzapine-induced hyperphagia associated with the development of obesity.
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1. Introduction
Antipsychotic-induced obesity is a serious side effect and requires a systematic and in depth
understanding of the molecular mechanisms involved in the progressive development of
obesity in order to develop appropriate therapeutic strategies. Clinical evidence indicates that
atypical antipsychotic-induced obesity (clozapine and olanzapine) occurs in three distinct
stages: rapid increases of body weight in the early acceleration stage (first 3 months); a reduced
rate of weight gain in the middle new equilibrium stage (3-18 months); and finally, body
weight plateaus and is maintained with continuing antipsychotic treatment (> 18 months, late
stage) (Allison and Casey, 2001; Pai et al., 2012). In rats, it has been shown that
olanzapine-induced obesity has similar patterns of weight gain although each period is shorter
(Huang et al., 2006). These findings suggest that the mechanisms may vary during the different
stages of olanzapine-induced obesity development.

In the clinic, antipsychotics’ affinity for the H1 receptor predicts (Kroeze et al., 2003) and
correlates (Matsui-Sakata et al., 2005) with antipsychotic-induced weight gain. In rats,
olanzapine treatment alters H1 receptor mRNA expression in the hypothalamus, which is
negatively correlated with weight gain (Han et al., 2008). Therefore, the H1 receptor
antagonism appears to be a key factor in olanzapine-induced obesity (Deng et al., 2010; He et
al., 2013). In fact, betahistine (an H1 receptor agonist/ H3 receptor antagonist) has been used to
prevent olanzapine-induced weight gain in humans (Poyurovsky et al., 2005; Poyurovsky et
al., 2013) and rats (Deng et al., 2012).
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Hypothalamic AMP-activated protein kinase (AMPK) regulates food intake. It has been
reported that histamine decreases pAMPK, which can be reversed by clozapine in mouse
hypothalamic slices (Kim et al., 2007). Furthermore, clozapine does not elevate pAMPK in H1
receptor knockout mice (Kim et al., 2007). Other investigators have reported that hypothalamic
AMPK is activated by olanzapine (Martins et al., 2010; Sejima et al., 2011; Skrede et al.,
2013). These data suggest a possibility that H1 receptor agonist may be used to reverse the
olanzapine-induced elevation of pAMPK and prevent olanzapine-induced obesity.

Since the mechanisms may vary during the different stages of olanzapine-induced obesity, two
key questions are: does hypothalamic H1 receptor-AMPK signaling play a different role in the
different stages of olanzapine–induced obesity; and is H1 receptor-AMPK signaling a potential
target for treating olanzapine-induced obesity? This study provides evidence for the first time
that the time-dependent modulating mechanisms of hypothalamic H1 receptor-AMPK
signaling underlie the three developmental stages of olanzapine-induced obesity. We tested the
effect of central H1 receptor activation in reducing olanzapine-induced hyperphagia and its
relationship with AMPK signaling in the hypothalamus.

2. Materials and Methods
2.1. Animals, drugs and chemicals. Female Sprague-Dawley (SD) rats (weight 200-225g)
were obtained from the Animal Resources Centre (Perth, WA, Australia). Rats were housed at
22°C on a 12h light-dark cycle (lights on 0700 h). Food and water were allowed ad libitum
throughout the study. All animal procedures were approved by the Animal Ethics Committee,
University of Wollongong, and complied with the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes (2004). Olanzapine (Zyprexa) was purchased from
4

Eli Lilly, Indianapolis, IN, USA. 2-(3-trifluoromethylphenyl) histamine (FMPH) and
pyrilamine were obtained from Sigma-Aldrich (Sigma, NSW, Australia).

2.2. Experiment one
To investigate the role of hypothalamic H1 receptor-AMPK signaling at the three stages of
olanzapine-induced weight gain, we conducted this experiment to detect changes of the H1
receptor-AMPK signaling under olanzapine treatment for 8, 16 and 36 days. A rat model that
mimics olanzapine-induced weight gain has been established in our laboratory (Zhang et al,
2013b). SD rats were randomly divided into three groups and treated with olanzapine for 8, 16
and 36 days to represent early, middle and late stages of olanzapine-induced weight gain
(Huang et al., 2006). Olanzapine (1 mg/kg) or vehicle was administered orally three times daily
(equivalent to 3 mg/kg/day) at eight-hourly intervals at 0700 h, 1500 h and 2300 h
(n=12/group). The rats were fed sweet cookie dough (62% carbohydrate, 22% protein, 6%
fibre, 10% vitamins and minerals) mixed with either olanzapine or placebo (Zhang et al,
2013b). Food intake and body weight were recorded every 2 days. The dosage of olanzapine
was chosen based on our previous studies (Zhang et al, 2013b). It was calculated towards the
clinical relevant dosage of 10mg/day (based on body surface area of different species)
(Reagan-Shaw et al., 2008), and mimicked the olanzapine -induced obesity in the clinical
setting. Two hours after the last drug treatment, the rats were euthanized using carbon dioxide
(CO2) asphyxiation (0900 h to 1100 h). The brains were immediately collected. The
hypothalami were quickly dissected on ice, frozen in liquid nitrogen and then stored at -80 °C.

2.3. Experiment two
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To address the question of whether direct activation of central H1 receptors could reduce
olanzapine-induced hyperphagia, and whether this effect is linked to hypothalamic AMPK
signaling, olanzapine-treated rats were given an intracerebroventricular (icv) injection of an
H1 receptor agonist. After acclimatization, each SD rat was surgically implanted with a
24-gauge guide cannula into the lateral ventricle under isoflurane anesthesia (1.0mm posterior
to the bregma, 1.5 mm lateral to the midline, and 3.5 mm below the top skull) (George and
Charles, 2007). After one week recovery, the rats were orally treated with olanzapine or
vehicle (same as in Experiment one) for 4 days. On day 5, the rats received 0, 100 or 200
nmoles

(Lecklin

et

al.,

1998)

icv

injection

of

the

H1

receptor

agonist,

2-(3-trifluoromethylphenyl) histamine (FMPH), or saline (n=5-8/group) at a rate of 5 µl/min,
and the volume was 5 µl (Group 1, vehicle/saline; Group 2, vehicle/FMPH 200 nmoles; Group
3, olanzapine/saline; Group 4, olanzapine/FMPH 100 nmoles; Group 5, olanzapine/FMPH 200
nmoles). Thirty minutes later, the rats were treated orally with olanzapine at the same dose or
with the vehicle. Food intake in all rats was measured at 1, 2, 4, 16 (overnight) and 24h after the
olanzapine or vehicle administration. To test whether the suppressive effect of FMPH 200
nmoles on food intake in olanzapine-treated rats could be reversed by H1 receptor antagonism,
the rats were given an icv injection of pyrilamine (800 nmoles) before FMPH was given, and
then food intake was tested (Group 6, olanzapine/FMPH 200 nmoles/pyrilamine 800
nmoles).To further examine the role of H1 receptor-AMPK signaling in olanzapine-induced
hyperphagia, the same treatment was repeated after a three day drug washout period. Rats were
then sacrificed using CO2 asphyxiation 1 h after their last treatment (between 1200 h and 1400
h) to detect H1 receptor-AMPK signaling in the hypothalamus. The hypothalamic nuclei were
identified and dissected according to the standard rat brain atlas (George and Charles, 2007).
Briefly, rat brains were snap-frozen, cut at 500 µM coronal sections from Bregma -2.16 mm to
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-3.60 mm, -1.44 mm to -2.04 mm, and -2.16 mm to -3.60 mm, for arcuate nucleus (Arc),
paraventricular nucleus (PVN) and lateral hypothalamic area (LHA) respectively. The
temperature was set at -18°C. The nuclei were dissected using micro-punches (#57401,
Stoelting Co, Wood Dale, IL, USA) (Zhang et al, 2013b). The Arc was dissected in an
overlapping pattern over the third ventricle. Since the Arc is small, the punched tissue
primarily contained Arc, but the inclusion of adjacent brain areas cannot be ruled out, therefore
the punched tissue containing Arc was named as the mediobasal hypothalamus (MBH).

2.4. Real-time quantitative PCR
Real-time quantitative PCR was used to detect the mRNA expression of the H1 receptors,
AMPKα, acetyl-CoA carboxylase α (ACCα, a downstream target of AMPK),
corticotrophin-releasing hormone (CRH), leptin receptor and orexin-A. Dissected
hypothalamus was homogenized and RNA was isolated using PurlinkTM RNA Mini Kit (Life
Technologies, NSW, Australia) following the manufacturer’s instructions. RNA was
converted to cDNA using Superscript® VILOTM cDNA Synthesis Kit (Life Technologies).
RT-PCR was performed using LightCycler® 480 Real-Time PCR instrument (Roche Applied
Science, NSW, Australia) with the TaqMan® Gene Expression Assays (Life Technologies):
H1 receptor (assay no. Rn00566691_s1); AMPKα2 (assay no. Rn00576935_m1); ACCα
(assay no. Rn00573474_m1); CRH (assay no. Rn01462137_m1); leptin receptor (assay no.
Rn01433205_m1), neuropeptide Y (NPY) (Rn00821417_m1), agouti-related peptide (AgRP)
(Rn01431703_g1) and orexin-A (assay no. Rn00565995_m1). The β-actin (assay no.
Rn00667869_m1) was used as an endogenous control. The amplification was run for 40 cycles
of denaturation at 95°C followed by annealing/extending at 60°C. The 2-∆∆CT method was used
to calculate the results (Schmittgen and Livak, 2008).
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2.5. Western blot
Western blot was performed following the procedure previously described (du Bois et al.,
2012). Tissues were homogenized in NP40 cell lysis buffer (Life Technologies) containing a
protease inhibitor cocktail, beta-glycerophoshate and phenylmethanesulfonyl fluoride (Sigma,
NSW, Australia). Protein concentration was detected by DC protein assay (Bio-Rad
Laboratories, Gladesville, Australia). Proteins were loaded onto 4-12% Bis-Tris gels
(Bio-Rad). Following electrophoresis for 50 min at 200V, the proteins were transferred to
polyvinylidene difluoride (PDVF) membranes (100V for 1h) (Bio-Rad). Membranes were then
blocked for 1h in 5% bovine serum albumin (BSA) in tris buffered saline with 0.1% Tween 20
(TBST) and incubated with the primary antibodies in 1% BSA at 1:1000 overnight at 4°C for
AMPKα, ACC, and phospho-AMPKα (pAMPKα) (Cell Signaling Technology, Danvers, MA,
USA) and phospho-ACCα (pACCα) (Millipore, Billerica, MA, USA). Following washing in
TBST (3×5min), membranes were incubated with goat anti-rabbit (1:5000 Santa Cruz
Biotechnologies, Santa Cruz, CA, USA), and horseradish peroxidase conjugated secondary
antibody for 1h at 25°C. Immunoractive proteins were detected using the enhanced
chemiluminescence (ECL) kit (GE Healthcare, Rydalmere, NSW, Australia). The results were
quantified using Bio-Rad Quantity One software. The quantification was normalized to
β-actin, according to previous studies (Ferno et al., 2011).

2.6. Statistical analysis
The statistics were performed by the SPSS 19.0 program (Chicago, IL, USA). In Experiment
one, two-way analysis of variance (ANOVA) (olanzapine × time as repeated measure)
followed by an independent unpaired student’s t-test (two-tailed) were used to analyze the
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statistical differences of food intake and weight gain between olanzapine and control groups in
every 2 days. The differences in H1 receptor, AMPKα and ACCα mRNA expression, and
pAMPKα and pACCα protein expression were analyzed using an independent unpaired
student t-test (two-tailed). In Experiment two, Kruskal–Wallis H test followed by Mann–
Whitney U tests were used to compare the difference in food intake, the hypothalamic leptin
receptor, orexin-A, corticotrophin-releasing hormone (CRH) and NPY and AgRP mRNA
expression following the icv injection. One-way ANOVA followed by post hoc Tukey’s
multiple comparison were used to analyze the statistical differences of pAMPKα and pACCα
expression in different hypothalamic regions. Correlations were identified using Pearson’s
correlation. All data were presented as mean ± SEM. Statistical significance was defined as p
≤ 0.05.

3. Results
3.1. Hyperphagia contributed to rapid weight gain in the early stage of
olanzapine-induced obesity
Olanzapine treatment induced a significant elevation in food intake during the first 12 days
when it was measured every 48h (Figure 1A; two-way analysis of variance (olanzapine × time
as repeated measure) followed by an independent student’s t test for each time point, all p <
0.05, n=12/group) but not during day 14-36 (all p > 0.05, Student’s t test). Rats treated with
olanzapine had a higher body weight throughout the whole treatment period (all p < 0.05,
Student’s t test), during which olanzapine rapidly increased body weight in the first 12 days
(early stage), slowed down from day 13 to 28 (middle stage), and then reached a plateau from
day 29 to 36 (late stage) (Figure 1B). Pearson's correlations revealed that the cumulative food
intake was significantly correlated with body weight gain in the early stage of
9

olanzapine-induced obesity but not in the middle and late stages (Figure 1C, D, E). To confirm
the relationship between food intake and body weight in the different stages of weight gain,
food efficiency (grams of weight gained/grams of food consumed) was also calculated. At the
early stage, the food efficiency significantly increased in the olanzapine-treated group
compared with the control group (control vs. olanzapine: 0.034 ± 0.004 vs. 0.049 ± 0.002, p =
0.007, Student’s t test). In the middle and late stages, the food efficiency of the
olanzapine-treated rats was not significantly different to that of the control group (middle stage:
control vs. olanzapine: 0.021 ± 0.001 vs. 0.018 ± 0.004, p = 0.480; late stage: 0.013 ± 0.003 vs.
0.018 ± 0.007, p = 0.552, Student’s t test).
[Insert Figure 1 around here]
3.2. Olanzapine induced time-dependent changes of hypothalamic H1 receptor-AMPK
signaling differing in the three stages of obesity development
In order to investigate the role of hypothalamic H1 receptor-AMPK signaling in
olanzapine-induced obesity, rats were treated with olanzapine for 8, 16 and 36 days to
represent the three stages of olanzapine-induced weight gain. In the early stage, olanzapine
treatment induced a significantly elevated hypothalamic H1 receptor mRNA expression (125 ±
7%, p = 0.015 vs. control, n=5/group, Student’s t test) but an unchanged AMPKα2 and
acetyl-CoA carboxylase α (ACCα, a downstream target of AMPK) mRNA expression
compared to the control rats (Figure 2A). The hypothalamic pAMPKα expression (activated
AMPK) but not pACCα expression was significantly increased by olanzapine (Figure 2D, E;
124 ± 8%, p = 0.021; 119 ± 12%, p = 0.354, respectively, n=5-6/group, Student’s t test).
Importantly, Pearson’s correlation revealed that the pAMPKα and pACCα expression were
positively correlated with H1 receptor mRNA expression as well as the last 48h food intake
(Table 1). These data suggest that olanzapine-induced hyperphagia and weight gain are
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associated with the activation of AMPK via a blockade of H1 receptor by olanzapine. In the
middle stage, when the rats were no longer hyperphagic, both the changes in H1 receptor
mRNA expression and pAMPKα and pACCα protein expression vanished (Figure 2B, D, F).
In the late stage, olanzapine significantly increased hypothalamic H1 receptor mRNA
expression (130% ± 5, p = 0.046, Student’s t test) compared to the control rats (Figure C). The
H1 receptor mRNA expression was significantly positively correlated with weight gain (r =
0.712, p = 0.016). However, both the ACCα mRNA expression (Figure 2C; 80 ± 6%, p = 0.030,
Student’s t test) and the pAMPKα and pACCα protein expression were significantly decreased
compared with the control rats (Figure 2D, G; 84 ± 1%, p = 0.005; 79 ± 5%, p = 0.023,
respectively, Student’s t test). Notably, the pAMPKα expression was negatively correlated
with H1 receptor mRNA expression and weight gain (Table 1). These data suggest that as
olanzapine treatment was prolonged, AMPK activity declined and was less effective in
down-regulating food intake.
[Insert Figure 2 around here]
Since hypothalamic AMPK can also be inhibited by leptin and insulin (Minokoshi et al., 2004),
we measured the plasma leptin and insulin levels of rats with late stage olanzapine-induced
obesity. These rats had significantly increased plasma leptin than the control group (control vs.
olanzapine: 8.4 ± 1.8 vs. 15.0 ± 1.5 ng/ml; p = 0.027, n=6/group, Student’s t test). Their insulin
level was not significantly different (control vs. olanzapine: 1.2 ± 0.4 vs. 1.5 ± 0.3 ng/ml; p =
0.158, n=6/group, Student’s t test). These results suggest that leptin may be involved in
inhibiting AMPK signaling at the late stage of olanzapine-induced obesity.
[Insert table 1 around here]
3.3. Histamine H1 receptor agonist, 2-(3-trifluoromethylphenyl) histamine, attenuated
olanzapine-induced hyperphagia
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Having observed the importance of the central H1 receptor-AMPK signaling in
olanzapine-induced weight gain, we further investigated whether the direct activation of the
central H1 receptors could reduce olanzapine-induced hyperphagia and weight gain. The H1
receptor agonist, 2-(3-trifluoromethylphenyl) histamine (FMPH), was injected into the lateral
brain ventricle of rats treated with either olanzapine or vehicle for five days. Olanzapine
treatment significantly increased food intake and cumulative body weight gain from day 2
(Figure 3A and B). Rats on olanzapine treatment followed by an icv injection of saline
(controls) showed a significant increase in food intake in 1, 2, 4 and 16 h at 85%, 112%, 61%,
19%, respectively (Figure 3C; all p < 0.05 vs. vehicle/saline, Mann-Whitney U test). This
effect was significantly attenuated by central FMPH treatment from 1 to 16 h time points
(Figure 3C; Kruskal-Wallis H test for each time points: 1 h: H(5) = 13.251, p = 0.021; 2 h: H(5)
= 11.121, p = 0.049; 4 h: H(5) = 15.954, p = 0.007; 16 h: H(5) = 10.957, p= 0.052; 24 h: H(5)
= 8.139, p = 0.149, n = 5-8/group). Olanzapine-induced hyperphagia was reduced by 64%,
51%, 44%, 21%, respectively as measured at 1, 2, 4 and 16 h by FMPH 200 nmoles (all p <
0.05 vs. olanzapine/saline, Mann-Whitney U test). The inhibitory effect of FMPH 100 nmoles
was also evident, with the most significant changes found in 4 and 16 h at 42% and 28%,
respectively ( p= 0.003, p = 0.073 vs. olanzapine/saline, Mann-Whitney U test). However, the
FMPH 200 nmoles injection did not significantly reduce food intake at any time points tested
compared with the controls (all p > 0.05 vs. vehicle/saline, Mann-Whitney U test). We also
investigated whether blocking the H1 receptor could reverse the effect of FMPH on food intake
in olanzapine-induced hyperphagia, by treating rats with pyrilamine 800 nmoles (an H1
receptor antagonist) before FMPH was given. However, pyrilamine 800 nmoles was not able to
reverse the effect of FMPH on food intake at all-time points (all p > 0.05 vs. olanzapine/FMPH
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200nmols, Mann-Whitney U test). These data suggest that the activation of the central H1
receptor is effective for treating olanzapine-induced weight gain.
[Insert Figure 3 around here]
3.4. FMPH treatment inhibited olanzapine-induced AMPK activation in the
hypothalamic mediobasal hypothalamus (MBH)
To understand the mechanisms by which FMPH attenuated olanzapine-induced hyperphagia,
we tested the dose dependent effect of FMPH on AMPK signaling in olanzapine-treated rats.
We examined the effect of olanzapine and FMPH on AMPK signaling in specific
hypothalamic regions including the MBH and paraventricular nucleus (PVN) as these regions
are significantly involved in H1 receptor (Sakata et al., 1988; Fukagawa et al., 1989; Ookuma
et al., 1989; Umehara et al., 2010) and AMPK (Lage et al., 2008; Lopez et al., 2008) regulation
of food intake. In the MBH, we found that olanzapine treatment significantly increased
pAMPKα (127 ± 8% vs. vehicle/saline) and pACCα (134 ± 9% vs. vehicle/saline) expression
compared with the vehicle-treated rats (Figure 4A, B; ANOVA, F(5,28) = 2.867, p = 0.033; F(5,31)
= 4.312, p = 0.004, respectively, n=5-7/group, Tukey post hoc tests). Injecting 200 nmoles
FMPH significantly decreased pAMPKα and pACCα expression compared with saline in the
olanzapine-treated rats (101 ± 3%, p = 0.040; 99% ± 6%, p = 0.046, respectively, Tukey post
hoc tests). FMPH 100 nmoles did not attenuate the olanzapine-induced activation of pAMPKα
(110 ± 5%) and pACCα (127 ± 8%) in the MBH (p > 0.05, Tukey post hoc tests). Consistent
with food intake data, the pyrilamine treatment did not significantly reverse the suppressive
effect of FMPH on hypothalamic pAMPKα (107 ± 6%) and pACCα (101 ± 9%) in
olanzapine-treated rats (p > 0.05, Tukey post hoc tests). It was noted that the pAMPKα
expression positively correlated with food intake at 1h (Table 2). These data suggest that the
central activation of the H1 receptors reduced the olanzapine-induced food intake, probably via
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the inhibition of MBH AMPK signaling. However, in the PVN, olanzapine treatment did not
significantly increase the pAMPKα and pACCα expression compared with vehicle (Figure
4C).
[Insert Figure 4 around here]
3.5. FMPH increased the mRNA expression of CRH in the PVN in olanzapine-treated
rats
The histaminergic system is associated with CRH, leptin and orexin-A in body weight
regulation (Gotoh et al., 2005; Jorgensen et al., 2005). Therefore we examined the effect of
olanzapine and FMPH on hypothalamic CRH, leptin receptor and orexin-A expression 1 h after
the last drug treatment. A previous study showed that olanzapine reduces CRH release under
the condition of K(+)-stimulation (Tringali et al., 2009). In our study (Figure 5A), olanzapine
did not significantly decrease PVN CRH mRNA expression (60 ± 10% vs. vehicle/saline group,
p > 0.05, n=4-6/group, Kruskal-Wallis H test followed by Mann-Whitney U test). However,
CRH mRNA expression was significantly increased by both FMPH 200 nmoles and FMPH
100 nmoles compared with the olanzapine/saline group (172 ± 37%, p = 0.033; 88 ± 6%, p =
0.043, respectively, Mann-Whitney U test). Compared with the vehicle/saline group, a single
injection of 200 nmoles FMPH did not significantly increase CRH mRNA expression (147 ±
28%, p = 0.251, Mann-Whitney U test). In addition, olanzapine decreased the expression of the
leptin receptor in the MBH (86 ± 3% vs. vehicle/saline, p = 0.028, n=4-6/group,
Kruskal-Wallis H test followed by Mann-Whitney U test) compared with the vehicle, and this
decrease could not be reversed by 200 nmoles or 100 nmoles FMPH (Figure 5B). The
histaminergic system innervates the orexin-A system associated with food intake and body
weight regulation (Gotoh et al., 2005; Jorgensen et al., 2005). However, we found that
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orexin-A mRNA expression was not changed by either the 5 day olanzapine treatment or the
central acute administration of FMPH (Figure 5C).

Neuropeptides in the hypothalamus including neuropeptide Y (NPY) and agouti-related
peptide (AgRP) are also important parameters in causing olanzapine-induced weight gain
(Ferno et al., 2011; Zhang et al., 2014). Therefore, we examined the effect of olanzapine and
FMPH on the expression of MBH NPY and AgRP 1 h after the last drug treatment. Olanzapine
treatment for 5 days significantly increased MBH NPY and AgRP mRNA expression (Figure
5D, E; 154 ± 14%, p = 0.011; 137 ± 20%, p = 0.050, respectively, Mann-Whitney U test).
However, both 200 and 100 nmoles FMPH did not significantly attenuate the increased NPY
(Figure 5D; 122 ± 14%, p = 0.221; 137 ± 13% p = 0.142, Mann-Whitney U test) or AgRP
(Figure 5E; 112 ± 4%, p = 0.213; 119 ± 23%, p = 0.670, Mann-Whitney U test) mRNA
expression induced by olanzapine.
[Insert Figure 5 around here]
4. Discussion
The present data suggest that olanzapine-induced weight gain can be divided into three phases,
in which different modulating mechanisms are involved. Excessive food intake may be the
main reason for the rapid increase in body weight in short-term olanzapine treatment (early
stage). We demonstrated different roles of the hypothalamic H1 receptors and AMPK
signaling in the three different stages of olanzapine-induced obesity development. In the early
stage, in accordance with olanzapine-induced hyperphagia, we found increased hypothalamic
H1 receptor mRNA expression and activated AMPK signaling. We found positive correlations
between the pAMPK level and H1 receptor mRNA, food intake, and weight gain. This
suggests that olanzapine activates AMPK by blocking the H1 receptors in olanzapine-induced
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hyperphagia and body weight gain. This was supported by our further test that a single icv
injection of an H1 receptor agonist significantly attenuated olanzapine-induced hyperphagia
and AMPK activation. Coinciding with our findings, previous studies also reported the
activation of hypothalamic AMPK by olanzapine treatment (< 2 weeks) (Sejima et al., 2011;
Skrede et al., 2013). Although one study showed that short-term olanzapine treatment inhibited
hypothalamic AMPK activity (Ferno et al., 2011), their measurement of AMPK was done 20 h
after the last drug treatment, and thus the inhibition of pAMPK may be due to the negative
feedback mechanism caused by high body weight rather than being a direct effect of
olanzapine.
[Insert table 2 around here]
As treatment was prolonged, we found that alterations of hypothalamic H1 receptor-AMPK
signaling vanished (middle stage), followed by increased H1 receptor mRNA expression but
decreased pAMPK protein expression (late stage). The fact that AMPK phosphorylation
returned to normal and was then inhibited suggests that AMPK acts as an energy sensor by
negatively responding to positive energy balance. Hypothalamic AMPK activity is also
inhibited by insulin and leptin (Minokoshi et al., 2004; Lopez et al., 2008). In the present study,
we observed increased plasma level of leptin in the late stage of olanzapine-induced obesity.
This may contribute to the down-regulation of hypothalamic AMPK signaling. In fact, it has
been suggested that the combined effects of hyperinsulinemia and increased leptin secretion
may lead to the inhibition of hypothalamic AMPK activity in mice with diet-induced obesity
(Martin et al., 2006; Viollet et al., 2010).

During chronic olanzapine treatment, the continuous weight gain without hyperphagia
indicated that other factors besides AMPK may also be involved in olanzapine-induced weight
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gain. Previous evidence in clinical and animal models has demonstrated that olanzapine can
decrease energy expenditure, which leads to weight gain (Stefanidis et al., 2008; Cuerda et al.,
2011). Possibly, the decreased energy expenditure may largely account for the increase in
weight gain especially at the later stages. However, in the case of late stage olanzapine-induced
obesity, both hypothalamic pAMPK and its directly downstream target pACC expression were
decreased. This evidence indicates that hypothalamic AMPK may drive a negative energy
balance which is not strong enough to reduce the weight gained after chronic olanzapine
treatment, although the exact mechanism for the maintenance of heavy weight in the late stage
still requires further study. In fact, other studies have shown that AMPK signaling is decreased
in diet-induced obesity in rodents, including the whole mouse and rat hypothalamus (Fei et al.,
2012; Whittle et al., 2012) and the mouse hypothalamic PVN (Martin et al., 2006). Similarly,
the current study showed decreased hypothalamic AMPK signaling in obese rats induced by
chronic olanzapine treatment. In addition, data from our group and others have reported that
long term olanzapine treatment is associated with decreased BAT temperature, BAT
uncoupling protein 1 expression (Stefanidis et al., 2008; Zhang et al., 2013) and peroxisome
proliferator activated coactivator 1α (Zhang et al., 2013). These results could be a direct effect
of olanzapine on BAT via lowering sympathetic activity in the late stage. This can occur
independently of its effect on hypothalamic AMPK signaling. The hypothalamic H1 receptors
are involved in the regulation of energy expenditure, partly by regulating the sympathetic
outflow to BAT (Masaki et al., 2004; Yasuda et al., 2004; Hong et al., 2006; Masaki and
Yoshimatsu, 2006; Lundius et al., 2010). A recent review by our group has suggested that
second generation antipsychotics (including olanzapine) may also decrease energy expenditure
by blocking the H1 receptors in the central nervous system (He et al., 2013). In the present
study, at the late stage of olanzapine-induced obesity, H1 receptor mRNA was increased, and
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the H1 receptor mRNA expression was significantly positively correlated with weight gain.
Therefore, it is possible that during long-term olanzapine treatment, the antagonism of the
hypothalamic H1 receptors may contribute to an olanzapine-induced decrease in energy
expenditure and the maintenance of high body weight. Additionally, future studies on the
effect of olanzapine on browning markers on white adipose tissue would be helpful (Fisher et
al., 2012). Since chronic olanzapine treatment also increases subcutaneous and visceral white
adipose tissue (Weston-Green et al., 2011), it is desirable to examine whether olanzapine
treatment affects the expression of fat storage enzymes such as lipoprotein lipase and fatty acid
synthesis in inguinal subcutaneous and visceral white adipose tissue.

The mechanisms by which olanzapine up-regulates H1 receptor mRNA expression remains
unknown. It is possible that the increased H1 receptor mRNA expression was due to a negative
feedback loop of the H1 receptor antagonism. In addition, the H1 receptors display constitutive
activity (Bond and Ijzerman, 2006). Olanzapine, similar to clozapine, may work as an inverse
agonist of the H1 receptors which suppress the H1 receptor internalization, which in turn
results in H1 receptor up-regulation (Humbert-Claude et al., 2012).

Our study demonstrated that central H1 receptor activation attenuated olanzapine-induced
excessive food intake, supporting the statement that central H1 receptor antagonism
contributes to olanzapine-induced hyperphagia, and could be a potential target for the
treatment of olanzapine-induced obesity. Furthermore, the activation of AMPK in the MBH by
olanzapine was attenuated by the H1 receptor agonist. These findings suggest that AMPK acts
as a downstream target in H1 receptor-regulated food intake in the MBH, and this
nucleus-specific activation of AMPK may be of major importance in contributing to
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olanzapine-induced hyperphagia. Further studies that directly inject the H1 receptor agonist
into the Arc are required to confirm the role of Arc H1 receptor-AMPK signaling in
olanzapine-induced hyperphagia and weight gain. The H1 receptors and AMPK in the PVN are
also well-known for their role in regulating food intake (Sakata et al., 1988; Fukagawa et al.,
1989; Ookuma et al., 1989; Ookuma et al., 1993). However, the lack of AMPK activation in
the PVN in the present study suggests that PVN H1 receptor-AMPK signaling is unlikely to
contribute to short-term olanzapine-induced hyperphagia and weight gain.

Histamine/H1 receptor signaling can influence the CRH, leptin and orexin systems in food
intake and body weight regulation (Gotoh et al., 2005; Jorgensen et al., 2005). CRH originating
from the PVN exerts an anorexic effect and can be activated by histamine (Kjaer et al., 1994).
The H1 receptor agonist, 2-thiazolylethylamine (2-TEA), increased CRH expression in the
PVN, suggesting that activating H1 receptors may also regulate food intake via CRH (Kjaer et
al., 1992; Kjaer et al., 1998). Our study found that the injection of an H1 receptor agonist
dose-dependently increased CRH expression compared with saline in olanzapine-treated rats,
suggesting that the CRH may also act as a downstream hormone of histamine H1 receptor
signaling in olanzapine-induced obesity, however further studies are needed. Since the Arc is
responsible for leptin signaling in the regulation of energy balance, the decreased leptin
receptor expression in the MBH by olanzapine treatment may induce a resistance to leptin
(Panariello et al., 2012). In addition, one study suggested that orexin is involved in
antipsychotic-induced weight gain (Fadel et al., 2002). However, our study did not find any
change in orexin-A in the LHA under olanzapine or FMPH treatment. Moreover, this study
found an increased expression of NPY and AgRP in the MBH. This is consistent with previous
studies (Ferno et al., 2011; Zhang et al., 2014) and supports the important role of NPY and
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AgRP in olanzapine-induced weight gain. However, the olanzapine-induced increase of NPY
and AgRP cannot be completely reversed by a single injection of the H1 receptor agonist. This
suggests that the H1 receptor plays a partial role in the olanzapine-induced elevation of NPY
and AgRP.

In conclusion, our data have demonstrated that the effect of olanzapine on hypothalamic H1
receptor–AMPK signaling varies during the different stages of obesity development. At the
early stage, olanzapine activated hypothalamic AMPK signaling by blocking the H1 receptors
leading to hyperphagia. With a prolonged treatment, the rats became obese although the
excessive food intake was no longer present, suggesting that other parameters in addition to
food intake may also contribute to increased body weight. It is possible that olanzapine affects
other pathways related to metabolic regulation besides AMPK (Schmidt et al., 2013). However,
we cannot exclude the possibility that desensitization to the drug used, or other unknown
feedback mechanisms, may also contribute to the results observed in the present study. In
summary, the results of this study may shed light on the future pharmacological development
of targeting the H1 receptor–AMPK signaling to assist in minimizing the weight gain side
effect of olanzapine treatment.
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Figure legends

Figure 1. Effects of olanzapine (3 mg/kg/day, tid) on food intake (A) and weight gain (B)
during three stages of olanzapine-induced obesity, and the correlations between cumulative
food intake and body weight gain in these three stages (C, D, E). Rats were trained to eat
cookie dough containing olanzapine or vehicle as indicated for 36 days (see ‘Materials and
Methods’) (n=12/group). All data are presented as mean ± SEM. Statistical significance was
defined as p < 0.05 (* p < 0.05, ** p < 0.01 vs. control). FI, food intake; WG, weight gain.

Figure 2. Effects of olanzapine on the gene and protein expressions of hypothalamic H1
receptor-AMPK signaling after 8 days (early stage), 16 days (middle stage) and 36 days (late
stage) olanzapine treatment (n=5-6/group). A, B, C, The mRNA expression of the
hypothalamic H1 receptor, AMPKα2 and ACCα after 8, 16 and 36 days olanzapine treatment.
D, Western blot of representative samples in the early, middle and late stage of
olanzapine-induced obesity, displaying bands of AMPKα, pAMPKα, ACC, pACCα and actin
expression in the hypothalamus. E, F, G, Western blot analysis of the protein expression of
hypothalamic AMPKα, pAMPKα, ACC and pACCα after 8, 16 and 36 days olanzapine
treatment. All data are presented as mean ± SEM. Statistical significance was defined as p <
0.05 (* p < 0.05, ** p < 0.01 vs. control).
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Figure 3. Effects of an acute central injection of the H1 receptor agonist,
2-(3-trifluoromethylphenyl) histamine (FMPH), on olanzapine-induced increased food intake
(n=5-8/group). A and B, Food intake and cumulative body weight gain of the rats treated with
olanzapine significantly increased from day 2. C, FMPH dose-dependently inhibited
olanzapine-induced hyperphagia at different time points. All data are presented as mean ±
SEM. Statistical significance was defined as p < 0.05 (* p < 0.05, ** p < 0.01). H, high dose; L:
low dose; PY: pyrilamine; V/S, vehicle/saline; V/F(H), vehicle/FMPH 200 nmoles; O/S,
olanzapine/saline; O/F(L), olanzapine/FMPH 100 nmoles; O/F(H), olanzapine/FMPH 200
nmoles; O/F(H)/PY, olanzapine/FMPH 200 nmoles/pyrilamine 800 nmoles.

Figure 4.

Effects of an acute central injection of the H1 receptor agonist,

2-(3-trifluoromethylphenyl) histamine (FMPH), on the hypothalamic AMPK signaling in
olanzapine or vehicle-treated rats (n=5-7/group). A and B, Representative western blot and
densitometry analysis of pAMPKα and pACCα expression in the mediobasal hypothalamus of
the olanzapine or vehicle-treated rats receiving the icv injection of FMPH or saline. C, Western
blot analysis of protein expression of pAMPKα and pACCα in the hypothalamic PVN. All data
are presented as mean ± SEM. Statistical significance was defined as p < 0.05 (* p < 0.05; ** p
<0.01). V/S, vehicle/saline; V/F(H), vehicle/FMPH 200 nmoles; O/S, olanzapine/saline;
O/F(L), olanzapine/FMPH 100 nmoles; O/F(H), olanzapine/FMPH 200 nmoles; O/F(H)/PY,
olanzapine/FMPH 200 nmoles/pyrilamine 800 nmoles. MBH, mediobasal hypothalamus;
PVN, paraventricular nucleus.

Figure 5.

Effects of an acute central injection of the H1 receptor agonist,

2-(3-trifluoromethylphenyl) histamine (FMPH), on mRNA expressions of: CRH in the PVN
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(A), leptin receptor in the MBH (B), orexin-A in the LHA (C), NPY (D), and AgRP (E) in the
MBH in either olanzapine or vehicle-treated rats (n=4-6/group). All data are presented as mean
± SEM. Statistical significance was defined as p ≤ 0.05 (* p ≤ 0.05). V/S, vehicle/saline;
V/F(H), vehicle/FMPH 200 nmoles; O/S, olanzapine/saline; O/F(L), olanzapine/FMPH 100
nmoles; O/F(H), olanzapine/FMPH 200 nmoles; O/F(H)/PY, olanzapine/FMPH 200
nmoles/pyrilamine 800 nmoles. CRH, corticotropin-releasing hormone; LHA, lateral
hypothalamic area; MBH, mediobasal hypothalamus; PVN, paraventricular nucleus.
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Table 1 Correlations within the hypothalamic H1 receptor mRNA, pAMPKα and pACCα protein
expression, food intake and weight gain during the three stages of olanzapine-induced obesity.

Early stage

Middle stage

Late stage

pAMPKα

pACCα

pAMPKα

pACCα

pAMPKα

pACCα

r (P-value)

r (P-value)

r (P-value)

r (P-value)

r (P-value)

r (P-value)

H1R mRNA

0.718 (0.029*) 0.647 (0.043*)

-0.057 (0.875) 0.226 (0.505)

Last 48h FI

0.747 (0.021*) 0.647 (0.031*)

0.281 (0.431) -0.119 (0.713)

-0.225 (0.482)

0.117 (0.718)

Weight gain

0.717 (0.030*) 0.324 (0.332)

-0.432 (0.245) 0.159 (0.640)

-0.743 (0.009**)

-0.230 (0.447)

0.691 (0.027*)

0.160 (0.659)

pAMPKα

-0.798 (0.002**) -0.639 (0.025*)

0.585 (0.046*)

Abbreviations: FI: food intake; H1R: histamine H1 receptor; pACCα, acetyl CoA carboxylase phosphorylated
Ser79 at ACCα subunits; pAMPKα, AMP-activated protein kinase phosphorylated Thr172 at AMPKα subunits.
Statistical significance was defined as p < 0.05 (*, p < 0.05, **, p < 0.01). Significant correlations are indicated in
bold.

Table 2 Correlations within the MBH pAMPKα and pACCα protein expression and food intake during
FMPH and olanzapine treatment.
Food intake (1h)
r (P-value)
pAMPKα

0.694 (0.000**)

pACCα

0.240 (0.179)

MBH

Abbreviations: pACCα, acetyl CoA carboxylase phosphorylated at Ser79 at ACCα subunits; pAMPKα,
AMP-activated protein kinase phosphorylated Thr172 at AMPKα subunits; MBH, mediobasal hypothalamus.
Statistical significance was defined as p < 0.05 (**, p < 0.01). Significant correlations are indicated in bold.
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